Eight million people worldwide suffer from chronic inflammatory bowel disease (IBD). The first-line treatments are corticosteroids, followed by biotherapies or complex immunotherapies, which only 1/3 of patients respond to in the long term. These treatments can also lose their effectiveness over time and cause significant side effects.
IBD, like many inflammatory diseases, is associated with a deregulation of tryptophan metabolism. Specifically, IBD patients showed a particular metabolic profile with an overproduction of pro-inflammatory metabolites and an underproduction of anti-inflammatory tryptophan-derived metabolites.